Cure Today

Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer

Pembrolizumab showed a 44% pathological complete response rate in dMMR colon cancer patients, with a major pathological response in 57%. Minimal severe side effects were observed, with 8% experiencing ...
Nasdaq

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating ...
RAPS

FDA Approvals Roundup: Sutab, Keytruda, Vimpat

Sebela’s Sutab (sodium sulfate, magnesium sulfate, and potassium chloride) has been approved as a tablet-form preparation for colonoscopy, providing patients with an alternative to liquid-based ...
WebMD

Keytruda and Padcev: FDA Approves New Combination Therapy for Aggressive Bladder Cancer

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
Healthline

What Are the Signs That Keytruda Is Working?

Doctors monitor Keytruda’s effectiveness using imaging tests like CT or MRI scans to check tumor size. (Sometimes tumors may appear larger initially due to a phenomenon called pseudoprogression.) ...